Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

Background The EGFR gene encodes a protein that stimulates molecular pathways that
allow the growth and development of the tumor microenvironment. The current preferred …

19134 Background: Pertuzumab (P), a monoclonal antibody, targets the HER2 receptor and
prevents dimerization of HER2 and HER2, HER2 and HER1 or HER2 and HER3. P is active …

Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for
patients with EGFR mutation-positive (EGFR m+) advanced non-small-cell lung cancer …

Introduction The phase 3 RELAY global study (NCT02411448) revealed significant
improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM+ …

Background Erlotinib (E) targeted therapy in EGFR mutant non-small cell lung cancer
(NSCLC) can effectively reduce tumor burden; however, the durability of response is limited …

Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …

Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …

Background In EGFR mutated, metastatic (met) NSCLC, outcomes from EGFR tyrosine
kinase inhibitors (TKIs) have differed historically by mutation (mut) type present, with lower …

Background Resistance to first-generation or second-generation EGFR tyrosine kinase
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small …